Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a Parkinson's drug protect eyes in diabetes?

NCT ID NCT05132660

First seen Apr 21, 2026 · Last updated Jun 23, 2026 · Updated 14 times

Summary

This early-phase trial tests whether levodopa, a drug used for Parkinson's, can slow blood vessel changes in the eyes of people with diabetes. Researchers will give the drug or a placebo to 244 patients who show early signs of retinal electrical delays. The goal is to see if levodopa can preserve vision by slowing disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Atlanta VA Medical and Rehab Center, Decatur, GA

    Decatur, Georgia, 30033-4004, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Levodopa (Sinemet CR)

What this could lead to

If it works, this could point toward a new way to slow early diabetic retinopathy and prevent vision loss.

What could go wrong

This is a very early, small trial. Levodopa may not slow eye changes, and side effects like nausea or dizziness are possible.

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.